Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 206

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 206
---
 Securities Act, to disclose certain information relating to a particular sale of common shares offered by this prospectus by the Selling Shareholder, including with respect to any compensation paid or payable by the Selling Shareholder to any brokers, dealers, underwriters, or agents that participate in the distribution of such shares by the Selling Shareholder, and any other related information required to be disclosed under the Securities Act.

We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the common shares covered by this prospectus by the Selling Shareholder.

As consideration for its irrevocable commitment to purchase our common shares under the SEPA, we have issued to the Selling Shareholder 105,840 of our common shares as Commitment Shares upon execution of the SEPA. In addition, we have paid the Selling Shareholder a structuring fee of $25,000.

We also have agreed to indemnify the Selling Shareholder and certain other persons against certain liabilities in connection with the offering of our common shares offered hereby, including liabilities arising under the Securities Act, or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. The Selling Shareholder has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by the Selling Shareholder specifically for use in this prospectus or, if such indemnity is unavailable, to contribute certain amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

The Selling Shareholder has represented to us that at no time during the period commencing as of the time that the Selling Shareholder first contacted the Company regarding the specific investment in the Company contemplated by the SEPA and ending immediately prior to the execution of the SEPA has the Selling Shareholder engaged, directly or indirectly, any transactions with respect to our common shares, including any short sale or any transaction that establishes a net short position. The Selling Shareholders has agreed that, during the term of the SEPA, none of the Selling Shareholder, its officers or any entity managed or controlled by the Selling Shareholder will enter into or effect, directly or indirectly, any short sale or any transaction that establishes a net short position with respect to our common shares for its own